Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBITDA (2021 - 2025)

Prime Medicine's EBITDA history spans 5 years, with the latest figure at -$46.0 million for Q4 2025.

  • For Q4 2025, EBITDA fell 8.83% year-over-year to -$46.0 million; the TTM value through Dec 2025 reached -$201.1 million, down 2.65%, while the annual FY2025 figure was -$201.1 million, 2.65% down from the prior year.
  • EBITDA reached -$46.0 million in Q4 2025 per PRME's latest filing, up from -$50.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$16.4 million in Q3 2021 to a low of -$65.5 million in Q4 2023.
  • Average EBITDA over 5 years is -$44.2 million, with a median of -$45.9 million recorded in 2024.
  • The largest YoY upside for EBITDA was 37.69% in 2022 against a maximum downside of 80.96% in 2022.
  • A 5-year view of EBITDA shows it stood at -$62.9 million in 2021, then surged by 37.69% to -$39.2 million in 2022, then crashed by 67.06% to -$65.5 million in 2023, then soared by 35.43% to -$42.3 million in 2024, then fell by 8.83% to -$46.0 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's EBITDA are -$46.0 million (Q4 2025), -$50.5 million (Q3 2025), and -$52.6 million (Q2 2025).